Serum XXXX is not a correlate of prostate @entity5 , but does predict biochemical failure for lymph node positive disease.

@entity1 @entity251 @entity263 @entity5 @entity342 @entity3 @entity2786 @entity1486
Previously we found that serum @entity251 (serum-T) correlated with the development of distant @entity3 in @entity1 with clinically localized @entity263 treated with radiotherapy. In this report, the relationship of serum-T to lymph node positivity and to @entity1 outcome for @entity1 with regional lymph node involvement treated with @entity342 ablation alone was investigated. Serum-T was available in 514 of 854 @entity1 with clinically localized @entity263 who underwent pelvic lymphadenectomy at M.D. Anderson @entity5 Center between 1984 and 1993. Pretreatment prostatic acid phosphatase (PAP) and @entity1486 (PSA) were assayed in 98% and 95% of @entity1 , respectively. @entity342 ablation was achieved via orchiectomy or a luteinizing hormone releasing hormone agonist. Median follow-up was 66 months for the node positive subgroup (n = 92). Serum-T did not correlate with palpable stage, Gleason score, pretreatment PSA, or lymph node involvement. Age     60 years and pretreatment PAP > 0.8 mU/ml correlated significantly with higher serum-T. In lymph node positive @entity1 treated with @entity342 ablation, higher serum-T levels corresponded to both pretreatment PSA > 10 ng/ml and @entity2786 > 0.8 mU/ml. Serum-T predicted for biochemical failure, but not metastatic relapse or overall survival. Actuarial 5-year biochemical failure rate was 73% for serum T > 500 ng/dl and 57% for serum-T  <= 500 (p = 0.009). Multivariate analysis showed serum-T to be an independent correlate of rising PSA, both as a continuous (p = 0.001) or categorical (p = 0.037) variable. Serum-T did not significantly correlate with lymph node positivity, and therefore is not a marker for regional disease spread. However, serum-T was significantly associated with biochemical failure in node-positive @entity1 treated with @entity342 ablation alone.
